Aug 22, 2025 • Zacks Commentary
BULLISH
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
Aug 18, 2025 • Benzinga
SOMEWHAT-BULLISH
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer
ROCKVILLE, Md., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the appointment of Shiniu Wei as Chief Financial Officer ( CFO ) .
Aug 13, 2025 • Motley Fool
SOMEWHAT-BULLISH
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive.
Aug 12, 2025 • Benzinga
SOMEWHAT-BEARISH
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
CDC shooter's writings revealed anti-vaccine beliefs and distrust of COVID-19 shots. The NIH chief says that mRNA vaccines lack viability due to public distrust. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → A group of former U.S.
Aug 06, 2025 • Motley Fool
NEUTRAL
Arbutus ( ABUS ) Q2 Revenue Surges 529%
Arbutus Biopharma ( NASDAQ:ABUS ) , a biotechnology firm focused on treatments for chronic hepatitis B and RNA-based medicines, delivered GAAP results for Q2 2025 that greatly outpaced analyst expectations. The August 6, 2025 release showed GAAP revenue of $10.7 million, far above the $1.59 ...
Aug 06, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.